BiotechTube

Lenvatinib + Pembrolizumab

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Human Papilloma Virus

Conditions

Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease

Trial Timeline

Jul 18, 2025 → Dec 1, 2027

NCT ID
NCT04645602

About Lenvatinib + Pembrolizumab

Lenvatinib + Pembrolizumab is a phase 1 stage product being developed by Eisai for Human Papilloma Virus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04645602. Target conditions include Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (6)

NCT IDPhaseStatus
NCT04645602Phase 1Recruiting
NCT04209660Phase 2Active
NCT03776136Phase 2Completed
NCT03609359Phase 2Completed
NCT03006887Phase 1Completed
NCT02501096Phase 1/2Completed

Competing Products

20 competing products in Human Papilloma Virus

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
25
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
77
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
52
DolutegravirShionogiPhase 3
77
GSK1349572 + efavirenzShionogiPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
33
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
77
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
33
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
33
dolutegravirShionogiPhase 3
77
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
77
GSK1349572 + EfavirenzShionogiPhase 1
33
GSK1349572ShionogiPhase 1
33
GSK1349572 + PlaceboShionogiPhase 2
52
Dolutegravir + MethadoneShionogiPhase 1
33
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir PlaceboShionogiPhase 3
77
GSK1349572 + Rifampin + RifabutinShionogiPhase 1
33
DTG + BCV + TVRShionogiPhase 1
33

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85